Prediction of mortality in patients with coronary artery disease undergoing vasodilator stress testing: A comparison between 99mTc-tetrofosmin and 99mTc-sestamibi

Nuclear Medicine Communications

Volumn 28, Issue 6, 2007, Pages 457-463

  Adams, George L ^a   Shaw, Linda K ^a   Tuttle, Robert H ^a   Hanson, Michael W ^a   Pagnanelli, Robert ^a   Borges Neto, Salvador ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Prognosis; SPECT; Vasodilator

Indexed keywords

ADENOSINE; DIPYRIDAMOLE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TETROFOSMIN TC 99M; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; EXERCISE TEST; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PROPORTIONAL HAZARDS MODEL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; MALE; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VASODILATOR AGENTS;

EID: 34247597824     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328174442d     Document Type: Article

References (31)

1. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary artery disease. N Engl J Med 1979; 300:1350-1358.
2. Mark DB, Shaw LK, Harrell Jr FE, Hlatky MA, Lee KL, Bengtson JR, et al. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med 1991; 325:849-853.
3. Brown KA, Boucher CA, Okada RD, et al. Prognostic value of exercise thallium-201 imaging in patients presenting for evaluation of chest pain. J Am Coll Cardiol 1983; 1:994-1001.
4. Iskandrian AS, Hakki AH, Kane-Marsch S. Prognostic implications of exercise thallium-201 imaging in patients with suspected or known coronary artery disease. Am Heart J 1985; 110:135-143.
5. Hachamovitch R, Berman DS, Kiat H, Cohen I, Cabico JA, Friedman J, et al. Exercise myocardial perfusion SPECT in patients without known coronary artery disease: incremental prognostic value and impact on subsequent patient management. Circulation 1996; 93:905-914.
6. Hachamovitch R, Berman DS, Shaw LJ, Kiat H, Cohen K, Cabico JA, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. Circulation 1998; 97:535-543.
7. Vanzetto G, Ormezzano O, Fagret D, Comet M, Denis B, Machecourt J. Long term additive prognostic value of thallium-201 myocardial perfusion imaging over clinical and exercise stress test in low to intermediate risk patients: study in 1137 patients with 6-years follow-up. Circulation 1999; 100:1521-1527.
8. Pryor DB, Shaw L, McCants CB, Lee KL, Mark DB, Harrell Jr FE, et al. Value of the history and physical in identifying patients at increased risk for coronary artery disease. Ann Intern Med 1993; 118:81-90.
9. IMV Medical Information Division. 2003 Nuclear Medicine Market Summary Report. 1 December 2003.
10. IMV Medical Information division. 2003 Echocardiography Market Summary Report. 1 June 2005.
11. Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 1999; 33:2092-2197.
12. Wackers FJ, Berman DS, Maddahi J, Watson DD, Beller GA, Strauss HW, et al. Technetium-99m hexakis 2-methoxy-isobutyl isonitrile: human biodistribution, dosimetry, safety and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 1989; 30:301-311.
13. 99mTc-tetrofosmin: myocardial perfusion imaging agent-implications for a 1-day imaging protocol. J Nucl Med 1993; 34:1254-1259.
14. Jain D, Zaret BL. Technetium 99m tetrofosmin. In: Iskandrian AE, Verani MS (editors): New Developments in Cardiac Nuclear Imaging. Armonk, NY: Futura; 1998, pp. 29-58.
15. Jain D. Technetium-99m labeled myocardial perfusion imaging agents. Semin Nucl Med 1999; 29:221-236.
16. Flamen P, Bossuyt A, Franken PR. Technetium-99m-tetrofosmin in dipyridamole stress myocaridial SPECT imaging: intraindividual comparison with technetium-99m-sestamibi. J Nucl Med 1995; 36:2009-2015.
17. Acampa W, Cuocolo A, Sullo P, Varrone A, Nicolai E, Pace L, et al. Direct comparison of technetium 99m-sestamibi and technetium 99m-tetrofosmin cardiac single photon emission computed tomography in patients with coronary artery disease. J Nucl Cardiol 1998; 5:265-274.
18. Berman DS, Hachamovitch R, Kiat H, Cohen I, Cabico JA, Wang FP, et al. Incremental value of prognostic testing in patients with known or suspected ischemic heart disease: a basis for optimal utilization of exercise technetium-99m sestamibi myocardial perfusion single photon emission computed tomography. J Am Coll Cardiol 1995; 26:639-647.
19. Shaw LJ, Hendel R, Borges-Neto S, Lauer MS, Alazraki N, Burnette J, et al. Prognostic value of normal exercise and adenosine Tc-99m tetrofosmin SPECT imaging: results from the multicenter registry in 4,728 patients. J Nucl Med 2003; 44:134-139.
20. 99mTc Sestamibi. Radiology 2004; 232:58-65.
21. Pryor DB, Shaw LK, Harrel FE, Lee KL, Hlatky MA, Mark DB, et al. Estimating the likelihood of severe coronary artery disease. Am J Med 1991; 90:553-562.
22. Harris PJ, Harrel Jr FE, Lee KL, Behar VS, Rosati RA. Survival in medically treated patients with coronary artery disease. Circulation 1979; 60:1259-1269.
23. Pryor DB, Harrell Jr FE, Lee KL, Califf RM, Rosati RA. Estimating the likelihood of significant coronary artery disease. Am J Med 1983; 75:771-780.
24. Rosati RA, McNeer JF, Starmer CF, Mittler BS, Morris Jr JJ, Wallace AG. A new information system for medical practice. Arch Intern Med 1975; 135:1017-1024.
25. Ravizzini G, Hanson MW, Shaw LK, Wong T, Hagge RJ, Pagnanelli RA, et al. Efficiency comparison between Tc-99m tetrofosmin and Tc-99m sestamibi myocardial perfusion studies. Nucl Med Commun 2002; 23:203-208.
26. Borges-Neto S, Shaw LK, Tuttle RH, Alexander JH, Smith WT, Chambless M, et al. Incremental prognostic power of single photon emission computed tomographic myocardial perfusion imaging in patients with known or suspected coronary artery disease. Am J Cardiol 2005; 95:182-188.
27. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40:373-383.
28. Soman P, Taillefer R, Depuey G, Udelson JE, Lahiri A. Enhanced detection of reversible perfusion defects by Tc-99m sestamibi compared to Tc-99m tetrofosmin during vasodilator stress SPECT imaging in mild to moderate coronary artery disease. J Am Coll Cardiol 2001; 37:458-462.
29. Groutars RG, Verzijlbergen JF, Zwinderman AH, Tiel-Van Buul MM, Ascoop CA, van Hemel NM, et al. Incremental prognostic value of myocardial SPECT with dual-isotope rest. (201)Tl/stress (99m)Tc-tetrofosmin. Eur J Nucl Med Mol Imaging 2002; 29:46-52.
30. Galassi AR, Azzarelli S, Tomaselli A, Giosofatto R, Ragusa A, Musumeci S, et al. Incremental prognostic value of technetium-99m tetrofosmin exercise myocardial perfusion imaging for predicting outcomes in patients with suspected or known coronary artery disease. Am J Cardiol 2001; 88:101-106.
31. Port SC, Berman DS, Garcia EV. Imaging guidelines for nuclear cardiology procedures. II. American Society of Nuclear Cardiology. J Nucl Cardiol 1999; 6:G47-G84.